No Products on your Comparison List.
Your basket is empty.
Find out more
Show all species
Show all synonyms
Select your species and application
anti-Human s100b Antibodies:
anti-Rat (Rattus) s100b Antibodies:
anti-Mouse (Murine) s100b Antibodies:
Go to our pre-filtered search.
Human Monoclonal s100b Primary Antibody for IHC (p) - ABIN3043667
Huang, Zhu, Zhang, Zhu, Liu, Zhu, Wang, Li, Yang, Dong, Liu, Chen, Zhang, Yang, Deng, Fan, Wang, Liu, Ma, Fu, Wu: S100+ cells: a new neuro-immune cross-talkers in lymph organs. in Scientific reports 2013
Show all 35 Pubmed References
Human Polyclonal s100b Primary Antibody for WB - ABIN3044359
Liu, Zhang, Zhao, Cui, Cao, Guo: Effects of hypothermia on S100B and glial fibrillary acidic protein in asphyxia rats after cardiopulmonary resuscitation. in Cell biochemistry and biophysics 2015
Show all 17 Pubmed References
Human Polyclonal s100b Primary Antibody for ICC, IF - ABIN4351813
Chaichana, Guerrero-Cazares, Capilla-Gonzalez, Zamora-Berridi, Achanta, Gonzalez-Perez, Jallo, Garcia-Verdugo, Quiñones-Hinojosa: Intra-operatively obtained human tissue: protocols and techniques for the study of neural stem cells. in Journal of neuroscience methods 2009
Show all 6 Pubmed References
Human Monoclonal s100b Primary Antibody for IHC, ELISA - ABIN969391
Sorci, Riuzzi, Arcuri, Giambanco, Donato: Amphoterin stimulates myogenesis and counteracts the antimyogenic factors basic fibroblast growth factor and S100B via RAGE binding. in Molecular and cellular biology 2004
Show all 3 Pubmed References
Mouse (Murine) Polyclonal s100b Primary Antibody for IHC, WB - ABIN3021048
Yao, Zhao, Tang, Xiong, Zhao, Liu, Dong, Zou, Cai: Blockade of β-catenin signaling attenuates toluene diisocyanate-induced experimental asthma. in Allergy 2017
Show all 2 Pubmed References
Human Polyclonal s100b Primary Antibody for IHC, WB - ABIN6672223
Yao, Zhao, Tang, Liang, Liu, Dong, Zou, Cai: The receptor for advanced glycation end products is required for β-catenin stabilization in a chemical-induced asthma model. in British journal of pharmacology 2017
Show all 2 Pubmed References
Human Polyclonal s100b Primary Antibody for WB - ABIN542005
Reeves, Yao, Crowley, Buck, Zhang, Yarowsky, Gearhart, Hilt: Astrocytosis and axonal proliferation in the hippocampus of S100b transgenic mice. in Proceedings of the National Academy of Sciences of the United States of America 1994
Show all 2 Pubmed References
Human Monoclonal s100b Primary Antibody for IHC, ELISA - ABIN966987
Shapiro, Marks, Whitaker-Azmitia: Increased clusterin expression in old but not young adult S100B transgenic mice: evidence of neuropathological aging in a model of Down Syndrome. in Brain research 2004
Show all 3 Pubmed References
Human Polyclonal s100b Primary Antibody for CM, ICC - ABIN2747403
Ito, Minamiya, Kawai, Saito, Saito, Nakagawa, Imai, Hirokawa, Ogawa: Tumor-derived TGFbeta-1 induces dendritic cell apoptosis in the sentinel lymph node. in Journal of immunology (Baltimore, Md. : 1950) 2006
Human Polyclonal s100b Primary Antibody for IF (p), IHC (p) - ABIN676703
Zhang, Li, Lu, Liu et al.: Cerebral potential biomarkers discovery and metabolic pathways analysis of ?-synucleinopathies and the dual effects of Acanthopanax senticosus Harms on central nervous system through metabolomics ... in Journal of ethnopharmacology 2015
In patients treated with ipilimumab and nivolumab, baseline S100B and increasing S100B levels of >145% as well as baseline LDH were associated with impaired overall survival (OS) whereas increasing LDH of >25% was not (P = .64). S100B could serve as a strong baseline marker for OS in melanoma patients receiving anti-PD-1 therapy
Results suggest that the prognostic biomarker S-100beta protein has a low clinical value to identify patients at risk of persistent post-concussion symptoms
This study demonstrated that the T allele at the rs9722 locus of the S100B gene was a significant risk factor for severe Hand, Foot, and Mouth Disease.
Study shows that longitudinally, there were no significant associations between changes in brain imaging parameters and S100beta after false discovery rate correction. These data provide some weak evidence that S100beta may be an informative biomarker of brain white matter aging.
serum levels elevated in diabetic ketoacidosis
This study investigated a fragment of the disordered p53 C-terminal domain (CTDf) that interacts with one of its partner molecules, S100B, as a representative Intrinsically disordered regions (IDRs).
S100B was an independent prognostic factor
Study reports of an association between S100B mRNA and mercury exposure in humans. Study reports a significant correlation between mercury content in hair and S100B mRNA levels in blood.
CSF-S100B might be a potential candidate biomarker for neuromyelitis optica spectrum disorder in discriminating, evaluating severity, and predicting disability.
S100B may be involved in the FGFR1-mediated inflammatory response during OA, which may be considered as a potential therapeutic target.
Elevated serum level of S100B in patients with multiple traumas combined delirium prior to ICU discharge is closely associated with poor clinical prognosis
strong association between serum S100B and peripheral neuropathy in neuropsychiatric systemic lupus erythematous
rs9722, a functional SNP in the 3'-UTR of the S100B gene, was strongly associated with age of onset of Parkinson's disease.
The S100B gene rs9722 polymorphism may contribute to the susceptibility of IS.
It is unclear if the higher S100B concentration in football players playing at least 50 plays was caused by exercise or impacts. Therefore, if serum S100B is to be used as a biomarker of impacts, and possible brain injury in sport, exercise time and intensity should be taken into account as confounding variables.
High S100B expression is associated with chemoresistance in ovarian cancer.
The serum levels of S100B in Groups A and B rose after the injury and reached a peak on the 4th day of injury. Serum levels of NSE and S100B protein can reflect the degree of spinal cord injury.
Serum levels of S100B (and neuron-specific enolase) at admission were related to initial Glasgow Coma Scale (GSC) scores, and these levels one week after traumatic brain injury were related to six month GSC scores.
Studied use of serum S100B as a biomarker to predict injury in patients with mild head injury. Found patients with cranial injury detected by CT, had higher S100B protein levels than those without cranial injury.
The expression of serum S100beta in patients with postoperative cognitive dysfunction was significantly increased
levels of S100B differentially affect skeletal muscle repair upon acute injury and in the context of muscular dystrophy, and S100B might be regarded as a potential molecular target in Duchenne muscular dystrophy .
Our findings demonstrate that S100B promotes microglia M1 polarization to aggravate cerebral ischemia, and provide a better understanding on the therapeutic effects of S100B and/or its antagonist/neutralization antibody in stroke.
S100B may be a promising target for pharmacological interventions aimed at repressing diabetes.
Data (including data from studies in knockout mice) suggest that S100b acting as a humoral factor impairs glycolysis in muscle (myoblasts, myotubes, and skeletal muscles) independent of insulin action; this effect appears to be due to inhibition of Gapdh activity from enhanced poly(ADP-ribosyl)ation of Gapdh. (S100B = S100 protein, beta polypeptide, neural; Gapdh = glyceraldehyde-3-phosphate dehydrogenase)
S100B inhibits C3H/10T1/2 murine embryonic mesenchyma.l cells into osteoblasts. S100B stimulates C3H/10T1/2 cell differentiation into adipocytes.
The results of this study showed that S100B affects behavioral despair in female mice through functional interaction with the 5-HT7 receptor.
Data show that S100B has direct effects on macrophages, enhancing particularly CCL22 and IL-1beta expression and modulates the inflammatory response in uveoretinitis and this is likely to be, at least in part, via a direct effect on macrophages.
Data show that high glucose increased protein-protein interaction between Steap4 and S100B in mesangial (MES13) cells.
high glucoseinduced profibrotic genes (TGFbeta, type IV collagen and fibronectin) and cell hypertrophyrelated p21WAF1 are dependent on S100B.
S100A1 and S100B are dispensable for endochondral ossification during skeletal development.
Data suggest up-regulation of S100b/RAGE (advanced glycosylation end-product receptor) signaling plays role in inflammatory interaction between adipocytes/macrophages; adipocyte secretion of S100b is up-regulated by Tnf (tumor necrosis factor-alpha).
Gioma production of S100B enhancestumor growth through CCL2 upregulation and tumor-associated macrophages chemoattraction.
HMGB1, S100B, and RAGE signaling modulate the hippocampal inflammatory response and might play key roles in surgery-induced cognitive decline.
S100B is a proinflammatory cytokine bridging RAGE and CD166/ALCAM downstream effector mechanisms, both being compensatory upregulated after genetic deletion of its counterpart.
S100B expression may serve to modulate cardiac metabolism and adverse consequences of AGE in diabetic post-MI remodeling and function
S100B is expressed in mouse photoreceptor cone outer segments but not in rods.
The RAGE pathway may play an important role in STAT3 induction in glioma-associated macrophages and microglia, a process that may be mediated through S100B.
S100B and APP levels are simultaneously increased within Down syndrome neural progenitors, their secretions are synergistically enhanced in a paracrine fashion, and their overexpressions disrupt mitochondrial membrane potentials and redox states.
Unlike in the hippocampus-dependent tasks, S100B-KO mice were indistinguishable from wild-type mice in both cerebellum-dependent motor coordination and delay eyeblink conditioning.
Data support S100B inhibition as a novel strategy for reducing cortical plaque load, gliosis and neuronal dysfunction in Alzheimer disease (AD) and suggest that both extracellular as well as intracellular S100B contribute to AD histopathology.
As CSF-S100B levels in calves with neurologic diseases widely differed, the utility of CSF-S100B as a diagnostic marker for neurologic diseases in cattle remains inconclusive.
S100B might participate in the pathophysiology of brain inflammatory disorders via RAGE-dependent regulation of several inflammation-related events including activation and migration of microglia
X-ray crystallography was used here to characterize an interaction between Ca(2)(+)-S100B and TRTK-12, a target that binds to the p53-binding site on S100B.
Intracellular S100B might modulate myoblast differentiation by interfering with MyoD expression in an NF-kappaB-dependent manner.
S100b activates guanylate cyclase in a calcium-dependent manner [review]
Structural studies in combination with biochemical data are used to develop a model for calcium-induced activation of human nuclear serine/threonine kinase (NDR) kinase by S100B.
S100B shows a sufficient thermostability to resist pasteurization but not spry-drying in milk formulas for preterm and term infants.
Structures of pentamidine (Pnt) bound to Ca(2+)-loaded and Zn(2+),Ca(2+)-loaded S100B were determined by X-ray crystallography at 2.15 A (R(free)=0.266) and 1.85 A (R(free)=0.243) resolution, respectively.
S100B protein can regulate the inflammatory response of SF and may affect the repair of cartilage damage in osteoarthritis, and the mechanism may be related to the activation of FGF-2/FGFR1 signaling pathway.
The time course of S100B serum values following spinal cord decompression correlates with outcome; the initial degree of paresis is not a prognostic factor to predict outcome.
This study demonstrated that One singular glomerulus (mdG2) exhibits S100 and parvalbumin-positive fibers, apparently originating from all crypt cells plus some microvillous olfactory sensory neuronss.
The protein encoded by this gene is a member of the S100 family of proteins containing 2 EF-hand calcium-binding motifs. S100 proteins are localized in the cytoplasm and/or nucleus of a wide range of cells, and involved in the regulation of a number of cellular processes such as cell cycle progression and differentiation. S100 genes include at least 13 members which are located as a cluster on chromosome 1q21\; however, this gene is located at 21q22.3. This protein may function in Neurite extension, proliferation of melanoma cells, stimulation of Ca2+ fluxes, inhibition of PKC-mediated phosphorylation, astrocytosis and axonal proliferation, and inhibition of microtubule assembly. Chromosomal rearrangements and altered expression of this gene have been implicated in several neurological, neoplastic, and other types of diseases, including Alzheimer's disease, Down's syndrome, epilepsy, amyotrophic lateral sclerosis, melanoma, and type I diabetes.
S-100 calcium-binding protein, beta chain
, S-100 protein subunit beta
, S100 calcium-binding protein, beta (neural)
, protein S100-B
, S-100 protein beta chain
, S100 calcium-binding protein B
, S100 calcium-binding protein beta (neural)
, S100 protein, beta polypeptide, neural
, S100 protein, beta polypeptide
, S100 calcium binding protein, beta (neural)
, S100 calcium-binding protein, beta
, S-100 calcium-binding protein beta subunit